On April 25, Lilly announced that it is advancing the global withdrawal of the new soft tissue sarcoma drug Lartruvo (olaratumab). Lilly’s decision was mainly due to the fact that in the large phase III ANNOUNCE study after marketing, olaratumab failed to show survival benefit in both the treated… Continue Reading Lilly’s soft tissue sarcoma drug Olaratumab will withdraw from the world

  Pharmaceutical companies usually do their utmost to extend the patent protection period to prevent the listing of generic drugs in order to gain market exclusive rights. Fiercepharma recently released a list of TOP10 drugs that lost exclusive rights in the United States in 2019, listing 10 varieties from seven… Continue Reading Top10 of drugs that lost exclusive rights in the US market in 2019

  Bispecific antibody (BsAb) refers to an antibody molecule that can specifically bind two antigens or two epitopes at the same time. In theory, it can exert synergistic effect of two monoclonal antibodies, which is one of the most popular new drug research and development investment direction in the industry.… Continue Reading Bispecific antibody boom

  At the end of 2018, Celgene understated the monotherapy of CD47 monoclonal antibody CC-90002 for the treatment of acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). On the day of the suspension of the CC-90002 trial, shares in other CD47 companies such as Trillium, Forty Seven, and Surface… Continue Reading Second generation CD47 antibody: a new hot spot for tumor immunotherapy

  Metabolism involves a series of biochemical reactions that convert nutrients into metabolites that play an important role in maintaining cellular homeostasis and in response to intracellular and extracellular stimuli. Metabolic changes are one of the important features of tumors. In order to maintain sustained proliferation, tumor cells must adjust… Continue Reading The next wave of cancer immunotherapy – regulating metabolism

  On April 3, a study published in the journal Nature, scientists from Stanford University found that blocking the activity of protein CD22 with an antibody can improve cognitive behavior in aging mice. Dr. Tony Wyss-Coray, a professor of neuroscience, led the research. Dr. Wyss-Coray has been working for years… Continue Reading Is it difficult to develop Alzheimer’s disease “new drug”? This target may be a savior

  On March 25, AstraZeneca announced that the European Medicines Agency (EMA) officially approved its SGLT-2 inhibitor, Forxiga (Dalagide) as adjunctive therapy for insulin, for optimal use of optimal doses of insulin to control poor blood sugar. Type 1 diabetes patients (BMI ≥ 27). This is the first time that… Continue Reading SGLT-2 inhibitors first approved for the treatment of type 1 diabetes

  “Big Pharmaceuticals” has been committed to producing a wide range of innovative drugs for many years. For them, gene therapy may be the place to give birth to the next “miracle.” Gene therapy, as its name implies, is a treatment that replaces defective genes with normal genes and has… Continue Reading Gene therapy is the leader, attracting countless giants to compete!

  On March 7, the New England Journal of Medicine published the results of a Phase I study of BI 655139 in the treatment of generalised pustular psoriasis (GPP). Pustular psoriasis is a rare type of psoriasis, accounting for no more than 1%. It is usually divided into generalized pustular… Continue Reading Boehringer Ingelheim first in class monoclonal antibody is surprisingly effective for rare psoriasis

  In 1998, American scientists Andrew Fire and Craig Mello published a groundbreaking paper in Nature, confirming that double-stranded RNA (dsRNA) is the cause of post-transcriptional gene silencing (PTGS) in nematodes. They call this phenomenon RNA interference (RNAi).   The discovery of RNAi (Fig. 1) explains the confusing gene silencing… Continue Reading The world’s first RNAi drug “born” for 20 years and will “explode” in the next 10 years.